logo

Video encyclopedia

ImClone Systems

0:33

ImClone Systems

4:04

ImClone Systems founder Sam Waksal on drug pricing

5:29

Watch CNBC's full interview with ImClone Systems founder Sam Waksal

5:44

IOR ImClone insider trading scandal

1:21

ImClone Drug Launch Event

ImClone Systems Incorporated is a formerly independent biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. In 2014 the use of the ImClone brand name was retired and the former ImClone research and manufacturing sites were renamed Eli Lilly and Company.